Watch stocks you care about
The single, easiest way to keep track of all the stocks that matter...
Your own personalized stock watchlist!
It's a 100% FREE Motley Fool service...
This was a pivotal year for Seattle Genetics (Nasdaq: SGEN ) ; a biotech getting its first drug approved is always a pivotal event, even when it's widely anticipated.
Expect more of the same in 2012. Instead of an approval, it'll be sales figures that are the pivotal event for 2012.
In the third quarter, Seattle Genetics racked up $10 million in sales of its blood cancer drug Adcetris, a solid showing considering that the drug was approved only in the middle of the quarter. But it'll have to ramp up fairly quickly to justify its $2 billion market cap. At a price-to-sales ratio of 5, there's about $400 million in sales built into the price, so Seattle Genetics doesn't need an instant blockbuster like Vertex Pharmaceuticals' (Nasdaq: VRTX ) Incivek. But there isn't much room for a slip-up either; in a post-Dendreon (Nasdaq: DNDN ) world, investors will be watching the launch very closely.
Beyond the sales of Adcetris, Seattle Genetics needs to continue working on its pipeline. Approval of a second drug controlled by Seattle Genetics is still a few years away, but there's room for Adcetris to grow sales all by itself. The European marketing application was submitted by its partner Takeda earlier this year, so an approval should be coming shortly.
There's also potential to expand Adentris into different patient populations. It's in a phase 3 trial testing it as a maintenance treatment for Hodgkin's lymphoma after stem-cell transplant; Celgene (Nasdaq: CELG ) has used the same maintenance-therapy tactic to increase sales of Revlimid. That trial is still enrolling patients, so data won't be available until 2013. The company is also trying to move into first-line treatment in combination with chemotherapy, which could quadruple potential patients; look for a phase 3 trial to start next year.
Finally, and this shouldn't be overlooked, Seattle Genetics has licensed out its antibody drug conjugate technology to multiple partners. There's a total of 12 drugs in the clinic and more that are still in the preclinical stage, including Pfizer (NYSE: PFE ) and Abbott Labs (NYSE: ABT ) , which both signed up this year. Look for milestones to role in next year and another partnership or two would add to the long-term value of Seattle Genetics.
Looking for more high-tech stock ideas? Check out the Fool's free report "3 Hidden Winners of the iPhone, iPad, and Android Revolution," where you'll find three companies quietly cashing in on the booming smartphone and tablet PC markets. Get your free copy.